Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 27, 2026, titled "Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting".
Press Release Mar 27 2026
Filed with NSE · · 9 pages · English
Release
Sun Pharmaceutical Industries Limited on 6ix
Earlier from Sun Pharmaceutical Industries
- Press Release Mar 21 2026
- Press Release Mar 16 2026
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
- Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami
- U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
Later from Sun Pharmaceutical Industries
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
- Sun Pharma signs Definitive Agreement to Acquire Organon
- Press Release Apr 27 2026
- Organon Cancels First Quarter Earnings Call
- Sun Pharma To Acquire Organon
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries